Work With Us
Contact Us
Work With Us
Contact Us
Search
Home
About Us
Our Mission and Vision
Meet the Team
Board of Directors
Scientific Advisory Board
Our Science
About Macrocycles
Introducing MXMO
TM
Our Pipeline
Clinical Trials
Publications
What’s New
Investors
Press Releases
Events
Home
About Us
Our Mission and Vision
Meet the Team
Board of Directors
Scientific Advisory Board
Our Science
About Macrocycles
Introducing MXMO
TM
Our Pipeline
Clinical Trials
Publications
What’s New
Investors
Press Releases
Events
October 23, 2024
CID-078, a first-in-class oral macrocycle Cyclin A/B-RxL inhibitor, demonstrates anti-tumor activity in E2F-driven cancers
Click the poster to download.
